SkinBioTherapeutics (LON:SBTX) Releases Earnings Results

SkinBioTherapeutics (LON:SBTX) released its quarterly earnings data on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative net margin of 237.95% and a negative return on equity of 115.86%.

SkinBioTherapeutics Price Performance

SkinBioTherapeutics stock opened at GBX 23.83 ($0.31) on Friday. The firm has a fifty day moving average of GBX 20.16 and a 200-day moving average of GBX 16.70. SkinBioTherapeutics has a 52-week low of GBX 8.32 ($0.11) and a 52-week high of GBX 26.45 ($0.34). The company has a quick ratio of 10.01, a current ratio of 0.93 and a debt-to-equity ratio of 27.57. The firm has a market capitalization of £54.44 million, a P/E ratio of -14.66 and a beta of 2.01.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.